British biotech EyeBio raises a $65M Series A expansion to accelerate its clinical development program

EyeBio is a biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. Here are details of EyeBio‘s latest funding round :

🚀 Launch

2021

🏭 Industry

Biotechnology

🧠Management

David Guyer, Tony Adamis (Co-founders)

💸 Funding & Investors

INVESTMENT (Novembre 2023)$65 million (Series A)
INVESTORS (Novembre 2023)Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC and from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund.

🎯 Funding purpose

Accelerate its clinical development program and further build out its innovative retina pipeline.

🌐 Country HQ

UK (London)

Leave a Reply

Your email address will not be published.